gp120-α4β7 binding inhibitor 11 is an anti-HIV agent. gp120-α4β7 binding inhibitor 11 interferes the binding of HIV associated glycoprotein gp12G with the integrin α4β7 (IC50=1.64nM).

GP120, HIV-1 MN, a peptide, is utilized in researching HIV infection [1] [2].

gp120-IN-1 (compound 4e) is a potent HIV-1 gp120 inhibitor with an CC 50 of 100.90 μM and IC 50 of 2.2 μM. gp120-IN-1 inhibitis gp120-mediated virus enter into cells. gp120-IN-1 has anti-HIV-1 activity. gp120-IN-1 has dose-dependent cytotoxicity in SUP-T1 cells [1].

gp120-IN-2 (compound 4i) exhibits anti-HIV-1 activity which is a potent inhibitor of HIV-1 gp120 with an IC 50 of 7.5 μM and CC 50 of 112.93 μM. gp120-IN-2 dose-dependently shows cytotoxicity in SUP-T1 cells [1].

Peptide T acetate is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a synthetic octapeptide whose possible mechanism of action is the competitive inhibition of gp120 to the CD4 receptor as well as binding to vasointestinal peptide receptors and inhibiting cytokine action

Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a synthetic octapeptide whose possible mechanism of action is the competitive inhibition of gp120 to the CD4 receptor as well as binding to vasointestinal peptide receptors and in

Peptide T (TFA) is an octapeptide derived from the V2 region of HIV-1 gp120. It serves as a ligand for the CD4 receptor, effectively inhibiting the binding of HIV to the CD4 receptor.

Cell-permeable calmodulin (CaM) agonist that binds to the EF-hand/Ca2+-binding site; produces CaM-dependent activation of phosphodiesterase. Also binds to cytoplasmic sites on other Ca2+ channels, including NMDA and HIV-1 gp120-activated channels, inhibit

Peptide T amide is an octapeptide segment of HIV envelope gp120 and is used in AIDS therapy.

Retrocyclin-1, a Theta-defensin, selectively binds to carbohydrate-rich surface molecules such as fetuin, gp120 (K d =35.4 nM), CD4 (K d =31 nM), and galactosylceramide (K d =24.1 nM) [1], thereby shielding cells from HIV-1 infection.

Globotriaosycleramides are glycosphingolipids found in mammalian cell membranes that are synthesized from lactosylceramides . They act as receptors for Shiga and Shiga-like toxins in vitro and in vivo. Globotriaosylceramides accumulate in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. Globotriaosylceramides act as natural resistance factors to HIV infection, interacting with HIV gp120 to prevent its interaction with chemokine co-receptors and subsequent fusion of HIV to host cell membranes. This product contains a mixture of hydroxy and non-hydroxy fatty acid-containing globotriaosylceramides isolated from porcine red blood cells (RBCs).

Fostemsavir Tris (BMS-663068 Tris) is the prodrug of BMS-626529,is a oral, safe and effective inhibitor of HIV-1 attachment. It inhibits human immunodeficiency virus type 1 (HIV-1) infection by binding to gp120 and interfering with the attachment of virus to CD4+ T-cells.

Temsavir (BMS626529) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells.

CD4 (81-92) is a peptide that was previously found to inhibit gp120 binding, HIV-1 infectivity, and syncytium formation.

BMS-378806 is an orally bioavailable HIV-1 inhibitor that interferes with gp120-CD4 interaction.

Defensin HNP-3 is a peptide secreted by human polymorphonuclear leukocytes (PMNs) that has antimicrobial properties. It induces lysis of mammalian cells when used at a concentration of 25 μg/mL. It also inhibits growth of E. faecalis (ED50 = 100 nM) and clinical isolates of P. aeruginosa (MIC90 = 4 μM). HNP-3 binds to recombinant HIV-1 envelope glycoprotein (gp120) and human CD4 (Kds = 52.8 and 34.9 nM, respectively). It also binds to recombinant, immobilized human surfactant protein D (SP-D; Kd = 55.7 nM) and inhibits focus formation in Madin-Darby canine kidney (MDCK) cells infected with influenza A virus (IAV).

Complestatin is a compound extracted from Streptomyces lavendulae mycelia; on acid hydrolysis yields D-4-hydroxyphenylglycine & D-3,5-dichloro-4-hydroxyphenylglycine & acidic chromophore; inhibits gp120-CD4 binding. It is isolated from the culture broth of Streptomyces and has anti-HIV-1 activity. It has a role as a metabolite, an antimicrobial agent and an anti-HIV-1 agent.

INCB-9471 is a CCR5 antagonist with anti-HIV activity and inhibits the interaction between HIV-1 gp120.

DAPTA (Adaptavir) is an inhibitor of CCR5, shows potent anti-HIV activities.

inhibitor of human CCR5 binding to HIV-1 gp120

NBD-14270 is a potent HIV-1 entry antagonist that acts on 50 strains of HIV-1 pseudotyped virus (IC50: 89 nM). nBD-14270 is a pyridine analogue with low cytotoxicity (CC50>100 μM). nBD-14270 binds HIV-1 gp120 and exhibits significant antiviral activity (EC50<200 nM). EC50<200 nM).

Globotriaosycleramides are glycosphingolipids found in mammalian cell membranes that are synthesized from lactosylceramides . They act as receptors for Shiga and Shiga-like toxins in vitro and in vivo. Globotriaosylceramides accumulate in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. Globotriaosylceramides act as natural resistance factors to HIV infection, interacting with HIV gp120 to prevent its interaction with chemokine co-receptors and subsequent fusion of HIV to host cell membranes. This product contains a mixture of hydroxy fatty acid-containing globotriaosylceramides isolated from porcine red blood cells (RBCs).

BMS-378806 (BMS-806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.

Fostemsavir (BMS-663068) is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection.

HIV Peptide T (Peptide T), this synthetic octapeptide is an antiviral drug in the treatment of HIV infection. It mainly competitively inhibits the interaction between gp120 (HIV surface protein) and the CD4 receptor, while also interacting with the vascular intestinal The peptide (vasointestinal peptide, VIP) receptor binds homologously and blocks the production and action of cytokines to exert its effect.

NBD-556 is a small molecule mimetic of CD4. NBD-556 recognizes the HIV-1 envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding.

Zinlirvimab is a humanized IgG1-λ2 monoclonal antibody that neutralizes HIV by targeting the HIV-1 gp120 envelope glycoprotein, specifically the IIIB gp120 V3 loop [1] [2].

BMS-585248 is a highly effective HIV-1 adhesion inhibitor that targets the viral envelope protein gp120.

The effect of N-(3-phenyl-2-propenyl)-1-deoxynojirimycin (ppDNM) on the lectin binding to HIV-1 glycoprotein was analyzed by using biotinylated lectins of various sugar specificities as probes. ppDNM potentially inhibited HIV-1-induced syncytium formation and viral infectivity of HIV-1 without cytotoxicity. The lectin binding assay showed that ppDNM treatment reduced Con A binding to gp120 of HIV-1.

Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl is an HIV-1 inhibitor that functions by interacting with gp120, thereby preventing its binding to CD4. This mechanism helps to maintain CD4-dependent T cell function.

Feglymycin is a 13-amino acid peptide originally isolated from Streptomyces that has antibacterial and antiviral activities. It is active against Gram-positive bacteria (MICs = 32-64 μg/ml) and inhibits HIV viral replication in H9 cells (IC50 = ~5 μM). Feglymycin is also active against clinical isolates of HIV-1 from clades A-D, A/E, and G (EC50s = 0.5-6.7 μM). It interacts with gp120 and inhibits HIV-1 NL4.3 binding to human soluble CD4 (EC50 = 4.4 μM) and to CD4+ SupT1 T cells by 74.5% when used at a concentration of 10.5 μM. Feglymycin inhibits the E. coli peptidoglycan biosynthesis enzymes MurA and MurC (Kis = 3.4 and 0.3 μM, respectively) in a noncompetitive manner.

NBD-14189 is a potent HIV-1 entry antagonist, acting against HIV-1HXB2 pseudovirus (IC50: 89 nM).NBD-14189 binds HIV-1 gp120 and has a significant antiviral effect (EC50<200 nM).